Lepu Biopharma came into today on the back foot, with the stock down about 10% over the past month, and investors clearly questioning whether the earlier move into profitability can hold. The latest half year report now forces a sentiment reset. Revenue for H1 2026 reached C¥522.4m, yet net income from core operations was only C¥27.4m, a sharp contrast with the recent trailing figures that were lifted by a C¥290.4m one off gain.

The market reaction looks less like cool analysis and more like a tug of war between fear of an earnings comedown and hope that Lepu Biopharma’s new profit status is real. The stock’s P/E of 26.5x still prices in meaningful belief. The question is whether investors are correctly discounting the quality of those earnings or giving too much weight to a one off boost.

Is Lepu Biopharma’s P/E of 26.5x a fair reflection of its new profitability, or mostly a mirage created by that C¥290.4m one off gain? See how the market is really pricing this story in our valuation analysis for Lepu Biopharma

H1 2026 Earnings Summary

• Revenue, H1 2026 vs. H1 2025: C¥522.4m vs. C¥465.9m (change of about 12%)
• Net Income from Core Operations, H1 2026 vs. H1 2025: C¥27.4m vs. C¥41.7m (decline of about 34%)
• Basic EPS, H1 2026 vs. H1 2025: C¥0.02 per share vs. C¥0.024 per share (decline of about 18%)
• Trailing 12 Month Net Income from Core Operations, H1 2026 vs. H1 2025: C¥247.0m vs. a loss of C¥177.2m (swing to profit, heavily affected by a C¥290.4m one off gain)

Prefer clean charts instead of a dense wall of earnings figures and footnotes? See Lepu Biopharma’s full financial picture, including a clear view of its valuation, in our company report for Lepu Biopharma.

Lepu Biopharma: Profitability Signal With Caveats

Lepu Biopharma now has core net income of C¥27.4m for H1 2026 and a trailing 12 month profit of C¥247.0m. That confirms the business is no longer loss making at an operating level. Revenue of C¥522.4m sits above the prior half year and suggests the commercial platform around oncology assets is gaining some scale. For a pipeline heavy biopharma story, this combination of revenue and positive core earnings gives some support to investors who argue the platform can fund at least part of its own development.

Short Term Earnings Drag Feeds Skepticism

The bear case around Lepu Biopharma focuses on earnings quality and volatility. Core net income declined from C¥41.7m in H1 2025 to C¥27.4m in H1 2026, and basic EPS fell from C¥0.024 to C¥0.02. The trailing profit is heavily influenced by the C¥290.4m one off gain. Shareholders have also seen the stock fall about 10% over 30 days. That combination supports caution that current profitability may not yet be firmly established.

After a one off gain has such a large effect on Lepu Biopharma’s trailing profit, you might ask whether this earnings wobble is the whole story or just an early warning. Review our independent risk analysis for Lepu Biopharma which shows 1 important warning sign

Take Control Of Your Next Move

If Lepu Biopharma’s mix of core profitability and one off gains has you interested but cautious, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and wait for a setup that fits your plan. Once you decide to take a position, use the Portfolio Command Center to keep on top of key updates while filtering out the short term noise. For a broader view on what other investors are thinking, tap into the Community and weigh different perspectives against your own thesis. By spotting potential catalysts and risks early, you can act with more confidence and stay informed about market developments.

Seeking Alternatives Beyond Lepu Biopharma?

Fresh stock ideas can move quickly once momentum builds. Use these under the radar for now screeners before the crowd catches on and the best entry points drop away. Act now.

• Spot sturdy balance sheets before momentum takes off by scanning the list of solid balance sheet and fundamentals stocks (434 results). It highlights companies built to handle pressure while many investors are still looking elsewhere.
• Catch income workhorses while yields remain appealing by reviewing the 434 dividend fortresses. It highlights businesses focused on returning cash while prices have not fully adjusted.
• Position ahead of the next wave in power demand by checking the 39 power grid technology and infrastructure stocks. It highlights companies tied to grid upgrades while this theme is still early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.